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Background: Accumulating evidence has demonstrated a pathogenic role of advanced glycation end products
(AGEs) and receptors for AGEs (RAGE) in inflammation. Soluble RAGE (sRAGE), with the same ligands-binding
capacity as full-length RAGE, acts as a “decoy” receptor. However, there has been scanty data regarding AGEs and
sRAGE in adult-onset Still’s disease (AOSD). This study aimed to investigate AGEs and sRAGE levels in AOSD patients
and examine their association with clinical characteristics.
Methods: Using ELISA, plasma levels of AGEs and sRAGE were determined in 52 AOSD patients, 36 systemic lupus
erythematosus(SLE) patients and 16 healthy controls(HC). Their associations with activity parameters and disease
courses were evaluated.
Results: Significantly higher median levels of AGEs were observed in active AOSD patients (16.75 pg/ml) and active
SLE patients (14.80 pg/ml) than those in HC (9.80 pg/ml, both p < 0.001). AGEs levels were positively correlated with
activity scores (r = 0.836, p < 0.001), ferritin levels (r = 0.372, p < 0.05) and CRP levels (r = 0.396, p < 0.005) in AOSD
patients. Conversely, significantly lower median levels of sRAGE were observed in active AOSD patients (632.2 pg/
ml) and active SLE patients (771.6 pg/ml) compared with HC (1051.7 pg/ml, both p < 0.001). Plasma sRAGE levels
were negatively correlated with AOSD activity scores (r = −0.320, p < 0.05). In comparison to AOSD patients with
monocyclic pattern, significantly higher AGEs levels were observed in those with polycyclic or chronic articular
pattern. With treatment, AGEs levels declined while sRAGE levels increased in parallel with the decrease in disease
activity.
Conclusion: The elevation of AGEs levels with concomitant decreased sRAGE levels in active AOSD patients,
suggests their pathogenic role in AOSD.
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Advanced glycation end products (AGEs) result from
non-enzymatic glycation and glycoxidation of proteins,
lipids, or nucleic acids [1,2]. Inflammation leads to oxi-
dative stress and the consequent formation of reactive
carbonyl compounds, which are partly transformed into
AGEs [3,4]. The increased accumulation of AGEs has
been reported in pathophysiological situations such as
Alzheimer’s disease and inflammation [1-3]. The in-
creased accumulation of AGEs has also been shown
positively correlated with disease duration in systemic
lupus erythematosus (SLE) [5-7]. These observations
point to a pathogenic role of AGEs in inflammatory
diseases.
Identified as a signal transduction receptor for AGEs
[8,9], the receptor for AGEs (RAGE) consists of an N-
terminal V-type Ig-like domain, two tandem C-type
domains, a single transmembrane domain, and a short
C-terminal intracellular cytoplasmic tail [8]. Accumu-
lating evidence shows that RAGE plays critical role in
inflammatory processes [10,11], and RAGE polymor-
phisms are associated with susceptibility and disease
severity of lupus nephritis [12]. AGEs interact with
both types of RAGE, namely full-length RAGE and C-
truncated RAGE [13-15]. The interaction of AGEs with
full-length RAGE induces activation of intracellular
signaling and results in secretion of cytokines such as
TNF-α, which plays a major role in inflammatory re-
sponses [13,14].
RAGE also exists in soluble form, termed soluble C-
truncated RAGE (sRAGE), which lacks the transmem-
brane and cytosolic domains of the full-length RAGE.
The sRAGE has the same AGEs-binding capacity as full-
length RAGE [16], and may act as a “decoy” receptor by
binding ligands (such as AGEs) and preventing them
from interacting with full-length RAGE [17,18]. There-
fore, decreased sRAGE levels may enhance full-length
RAGE signaling and thereby augment inflammation. A
previous study demonstrated that rheumatoid arthritis
(RA) patients displayed lower sRAGE levels compared to
healthy subjects and osteoarthritis patients [19]. Recent
studies also observed low sRAGE levels in patients with
active inflammatory diseases, such as Takayasu’s arteritis
and SLE [20,21].
Adult onset Still’s disease (AOSD) is an inflammatory
disorder, characterized by fever, rash, arthritis, multi-
organs involvement, and increased acute phase reactants
[22-26]. Although the aetiopathogenesis of AOSD re-
mains unclear, cytokine-mediated inflammation may
contribute to the development of this disease [27-29].
Therefore, we hypothesize that inflammatory responses
in AOSD may be related to high AGEs levels and/or low
sRAGE levels, which may lead to enhanced production
of inflammatory mediators. However, there has beenscanty data concerning circulating levels of AGEs and
sRAGE in AOSD patients.
In this study, we examined plasma levels of AGEs and
sRAGE in AOSD patients, SLE patients, and healthy
subjects. Although AOSD has recently been considered
as an autoinflammatory, instead of autoimmune, disease
[30,31], we enrolled SLE patients as the disease control
because both diseases share partial clinical manifesta-
tions, and the expression of AGEs or sRAGE has been
observed in SLE [5,6,21]. The associations of AGEs and
sRAGE levels with clinical characteristics, activity pa-
rameters, and disease courses were also investigated.
Methods
Patients
In this monocentric and prospective study, 52 patients
with AOSD fulfilling the Yamaguchi criteria [32] were
enrolled consecutively. Patients with infections, malig-
nancies, or other rheumatic diseases were excluded. Dis-
ease activity of AOSD was assessed using a modified
Pouchot score described by Rau et al. [33], and active
AOSD was defined as a disease activity score of at least
3. All AOSD patients received corticosteroids and non-
steroidal anti-inflammatory drugs (NSAIDs). Besides, the
disease-modifying anti-rheumatic drugs (DMARDs) pre-
scribed included hydroxychloroquine (42 patients), metho-
trexate (40 patients), sulfasalazine (28 patients), and
azathioprine (12 patients). Defined as described in previous
studies [34,35], one of three patterns of disease course was
determined for each AOSD patient. Thirty-six patients ful-
filling the 1997 revised criteria of the American College of
Rheumatology (ACR) for SLE [36] were included as disease
controls. Disease activity of SLE was determined by calcu-
lating SLE disease activity index (SLEDAI) [37], and active
SLE was defined as a SLEDAI score of at least 6. Sixteen
healthy volunteers who had no rheumatic disease were the
normal controls. History of cigarette smoking, including
past and present smoking habit, was taken and body mass
index (BMI) was calculated as body weight in kilograms di-
vided by the square of body height in meters. To decrease
the influence of foods on AGEs levels, we advised the par-
ticipants to avoid foods high in AGEs, such as donuts and
dark-colored soda for at least one week before starting the
investigation. Venous blood samples taken in the early
morning were centrifuged at 1000 g for 10 min within
15 min of withdrawal, and all the plasma samples had been
stored at −70°C until used simultaneously for the deter-
mination of levels of AGEs or sRAGE. To avoid the poten-
tial effects of hypoglycemic agents, statins, and angiotensin
converting enzyme inhibitors (ACEI) on AGEs or sRAGE
levels [38-40], subjects receiving these medications were
excluded from this study. The ethics committee, the Insti-
tutional Review Board of Taichung Veterans General Hos-
pital (CE11010), had approved the design of this study and
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Determination of plasma levels of AGEs and RAGE using
ELISA
Plasma levels of total AGEs, which include Nε-Carboxy-
methyllysine (CML), pentosidine, and other AGE struc-
tures, were determined in all subjects using ELISA (Cell
Biolabs Inc., San Diego, CA, USA) according to the
manufacturer’s instructions. Plasma sRAGE levels were
determined using another ELISA (R&D Systems, Inc.,
Minneapolis, MN, USA) which detects total sRAGE
pool. The minimum detectable sRAGE level is 4.12 pg/
ml. All assays were performed with both inter- and
intra-assay coefficient of variation (CV) of less than 10%.
Statistical analysis
The results are presented as the mean ± SD or median
(interquartile range). Kruskal-Wallis test was used for
between-group comparison of AGEs or sRAGE levels.
When this test showed significant differences, the exact
p-value was then determined using the Mann–Whitney
U test. The correlation coefficient was obtained through
the nonparametric Spearman’s rank correlation test. A
logistic regression analysis was used to evaluate the ef-
fects of clinical characteristics and disease activity pa-
rameters on levels of AGEs or sRAGE in AOSD
patients. Wilcoxon signed rank test was employed to
compare the levels of AGEs and sRAGE during follow-Table 1 Demographic data and clinical characteristics of patie
systemic lupus erythematosus (SLE), and healthy controls (HC
AOSD (n = 52)
Age at study entry (years) 37.1 ± 13.4
Proportion of females 37 (71.2%)
Serum creatinine (mg/dL) 0.84 ± 0.14
Body mass index (kg/m2) 22.6 ± 2.7
AOSD activity scores 4.3 ± 2.0
CRP levels (normal <0.3 mg/dL) 2.66 ± 2.44
Ferritin levels (normal <280 μg/L) 1458 ± 4717
SLEDAI NA
C3 (normal 84–160 mg/dL) NA
C4 (normal 12–36 mg/dL) NA
Anti-dsDNA (normal <92.7U/mL) NA
Nephritis 0 (0.0%)
Smoker (past) 10 (19.2%)
Smoker (present) 6 (11.5%)
Hypertension 4 (7.7%)
Data are presented as mean ± SD or number (percentage); NA: not applicable.
CRP: C-reactive protein; SLEDAI: SLE disease activity index; C3: complement 3; C4: co
defined by persistent proteinuria (>0.5 g/24 hours) or pathological examination of ren
§p < 0.001, vs. Healthy controls.up in AOSD patients after effective therapy. A probabil-
ity of less than 0.05 was considered significant.Results
Clinical characteristics of AOSD patients and SLE patients
Among the 30 patients with active AOSD, spiking fever
(≥39°C), rash, arthritis, and lymphadenopathy were
noted in 30 (100%), 25 (83.3%), 18 (60.0%), and 7
(23.3%) patients respectively. Twenty-five SLE patients
had active disease (mean SLEDAI ± SD, 12.00 ± 1.11),
eleven (30.6%) with renal involvement, and 11 had in-
active disease (mean SLEDAI ± SD, 4.11 ± 0.63) at the
time of investigation. There were no significant differ-
ences in age at onset, proportion of females, BMI, or
proportion of past or present smoker between AOSD
patients and SLE patients or healthy subjects (Table 1).Plasma levels of AGEs in AOSD patients and SLE patients
As shown in Figure 1A and Table 2, significantly
higher AGEs levels were observed in active AOSD pa-
tients and active SLE patients than the levels in
healthy subjects. Significantly higher AGEs levels were
also observed in active AOSD patients compared with
inactive AOSD patients or inactive SLE patients. How-
ever, there was no significant difference in AGEs levels
between active AOSD patients and active SLE
patients.nts with adult-onset Still’s disease (AOSD), patients with
)#
SLE (n = 36) HC (n = 16)
38.0 ± 12.1 32.5 ± 6.1
30 (83.3%) 10 (62.5%)
0.96 ± 0.92 0.89 ± 0.17




10.0 ± 1.0 NA
86.9 ± 5.9 NA
19.6 ± 2.1 NA
251.4 ± 36.4 NA
11 (30.6%)** NA
7 (19.4%) 3 (18.8%)
5 (13.9%) 2 (12.5%)
9 (25.0%)*§ 0 (0.0%)
mplement 4; Anti-ds DNA: anti-double strand DNA antibody; Nephritis is
al biopsy specimens showing lupus nephritis. *P < 0.05, **p < 0.001, vs. AOSD.
Figure 1 Comparison of plasma levels of (A) AGEs and (B) soluble RAGE (sRAGE) among 30 patients with active adult-onset Still’s disease (AOSD),
22 patients with inactive AOSD, 25 patients with active systemic lupus erythematosus (SLE), 11 patients with inactive SLE, and 16 healthy subjects
(HC). The horizontal line indicates median value for each group. *p < 0.05, **p < 0.005, ***p < 0.001, was determined by Mann–Whitney U test.
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As shown in Figure 1B and Table 2, significantly lower
sRAGE levels were observed in active AOSD patients
and active SLE patients compared with healthy sub-
jects. Active AOSD patients also had significantly
lower sRAGE levels than inactive AOSD patients.
However, there was no significant difference in sRAGE
levels between active AOSD patients and active SLE
patients.Correlation between disease activity parameters and
AGEs levels or sRAGE levels
Plasma AGEs levels were positively correlated with dis-
ease activity parameters including clinical activity scores
(r = 0.836, p < 0.001), serum ferritin levels (r = 0.372, p <
0.05), and CRP levels (r = 0.396, p < 0.005) in AOSD
patients. Similarly, plasma AGEs levels were positively
correlated with SLEDAI (r = 0.831, p < 0.001) in SLE
patients. In contrast, plasma sRAGEs levels were
Table 2 Comparison of plasma AGEs levels and plasma
sRAGE levels in 52 patients with adult-onset Still’s
disease (AOSD), 36 patients with systemic lupus
erythematosus (SLE), and 16 healthy subjects (HC)
AGEs and sRAGE, patient groups Median (interquartile range)
AGEs levels, μg/mL
Active AOSD (n=30) 16.75 (12.45-24.66)**##§§§
Inactive AOSD (n=22) 7.02 (5.43-9.01)
Active SLE (n=25) 14.80 (10.68-21.42)**##§§
Inactive SLE (n=11) 6.49 (4.40-11.10)
HC (n=16) 9.80 (4.55-10.83)
sRAGE levels, pg/mL
Active AOSD (n=30) 632.2 (437.8-866.9)**#§§§
Inactive AOSD (n=22) 858.9 (599.8-1222.2)§
Active SLE (n=25) 771.6 (553.0-1069.1)*§§
Inactive SLE (n=11) 1480.0 (892.1-1686.9)
HC (n=16) 1051.7 (738.2-1468.3)
AGEs: advanced glycation end products; sRAGE: soluble receptor for AGEs.
*p<0.05, **p<0.001, versus HC; #p<0.05, ##p<0.001 versus inactive AOSD;
§p<0.05, §§p<0.005, §§§p<0.001, versus inactive SLE.
Mann-Whitney U test was used for between-group comparison of
numerical variables.
Table 3 Logistic regression analysis of plasma AGEs levels




AGEs levels sRAGE levels
B Beta p B Beta p
Univariate analysis
Smoking −1.00 −0.03 0.806 30.79 0.02 0.864
BMI −1.01 −0.28 0.056 23.07 0.14 0.314
Leukocytosis 5.31 0.27 0.055 −313.40 −0.36 0.010
Anemia 6.89 0.30 0.032 −308.35 −0.30 0.031
CRP 2.21 0.55 0.000 −8.63 −0.05 0.734
Log(Ferritin) 10.18 0.58 0.000 −0.02 −0.16 0.244
Activity score 3.81 0.77 0.000 −85.88 −0.39 0.004
Multivariate analysis
Activity score 2.63 0.53 0.000 −45.56 −0.21 0.062
AGEs: advanced glycation end products; sRAGE: soluble receptor for AGEs;
BMI: body mass index; CRP: C-reactive protein.
Leukocytosis is defined as white cell count >10,000/cumm; anemia is defined
as hemoglobin ≦11.3gm/dl.
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p < 0.05) in AOSD patients, as well as SLEDAI (r = −0.483,
p < 0.005) in SLE patients. In addition, there was an inverse
correlation between AGEs levels and sRAGE levels in
AOSD patients (r = −0.323, p < 0.05) and SLE patients
(r = −0.454, p < 0.01).Logistic regression analysis
Using univariate regression analysis, AGEs levels were
positively associated with the presence of anemia and
disease activity parameters such as CRP levels and fer-
ritin levels in AOSD patients (Table 3). Plasma sRAGE
levels were negatively associated with the presence of
anemia and leukocytosis in AOSD patients. Using uni-
variate and multivariate analysis, AGEs levels were posi-
tively correlated with activity scores, while sRAGE levels
were negatively correlated with activity scores in AOSD
patients.
The differences in plasma levels of AGEs and sRAGE in
AOSD patients with different patterns of disease course
Among all AOSD patients, 28 (53.8%) had polycyclic
systemic pattern, 12 (23.1%) had monocyclic systemic
pattern, and the remaining 12 (23.1%) had chronic ar-
ticular pattern. As illustrated in Figure 2, significantly
higher AGEs levels were observed in AOSD patients
with polycyclic pattern or chronic articular pattern com-
pared with those with monocyclic pattern. In contrast,
significantly lower sRAGE levels were demonstrated inAOSD patients with polycyclic pattern than those in pa-
tients with monocyclic pattern.Changes in plasma levels of AGEs and sRAGE in AOSD
patients after therapy
Sixteen AOSD patients were available for examination
both in the active phase and in the inactive phase after
6 months of treatment. As shown in Figure 2C and D,
AGEs levels significantly declined (mean ± SEM, 24.6 ±
2.7 pg/mL vs. 11.2 ± 1.6 pg/mL, p < 0.001) while sRAGE
levels increased (460.5 ± 55.8 pg/mL vs. 794.9 ± 77.0 pg/
mL, p < 0.001) significantly, paralleling the decreases in
clinical activity scores (5.88 ± 0.41 vs. 2.00 ± 0.20, p <
0.001) and CRP levels (4.07 ± 0.63 pg/ml vs. 0.97 ±
0.26 pg/ml, p < 0.001) in AOSD patients after 6-month
therapy.
Discussion
This is the first study to examine plasma levels of AGEs
and sRAGE in AOSD patients, and to characterize their
association with activity parameters of this disease.
Plasma AGEs levels were significantly higher in active
AOSD patients compared with inactive AOSD patients
or healthy subjects, with the levels positively correlated
with activity parameters. In contrast, plasma sRAGE
levels were significantly lower in active AOSD patients
compared with inactive AOSD patients or healthy sub-
jects, with their levels negatively correlated with activity
parameters. Moreover, the decrease in AGEs levels and
an increase in sRAGE levels paralleled disease remission.
These observations indicate that overproduction of
AGEs and a reverse regulation of sRAGE may be
Figure 2 Comparison of plasma levels of (A) AGEs and (B) soluble RAGE (sRAGE) among AOSD patients with different patterns of disease courses,
including 12 patients with monocyclic pattern, 28 patients with polycyclic pattern, and 12 patients with chronic arthritis. The horizontal line indicates
median value for each group. *p < 0.05, **p < 0.005, was determined by Mann–Whitney U test. The changes in (C) plasma levels of AGEs as well as
sRAGE and (D) disease activity parameters including clinical activity scores and C-reactive protein (CRP) levels in 16 AOSD patients after 6 months of
treatment. Rx.: treatment. Data are presented as mean ± SEM. *p < 0.005, versus before treatment, determined by the Wilcoxon signed rank test.
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indicators of this disease.
RAGE, the most characterized receptor of AGEs, ap-
pears to play an important role in inflammatory re-
sponses [9-12]. Soluble RAGE (sRAGE), the extracellular
domain of RAGE, is generated by two distinct mecha-
nisms, the splice variant [endogenous secretory RAGE
(esRAGE)] secretion and cleavage of membrane-bound
RAGE (cRAGE) through metalloproteinase [15,16]. Both
esRAGE and cRAGE are functionally equivalent and
interact with the same RAGE ligands. The sRAGE acts
as a decoy receptor, and effectively blocks the binding of
AGEs or other ligands to cell membrane-bound RAGE
[17,18], which may explain the inverse correlation be-
tween sRAGE levels and AGEs levels in AOSD patients.
The reduction of sRAGE levels may also represent an in-
adequate protective response in inflammatory diseases.
Likewise, circulating sRAGE levels have been shown to
be decreased in patients with RA [19], Takayasu’s arter-
itis [20], SLE [21], and Still’s disease [41]. In agreement
with previous findings that decreased sRAGE levels were
negatively correlated with disease activity in patients
with Still’s disease [41], we similarly demonstrated sig-
nificantly lower sRAGE levels in active AOSD patients
than those in quiescent AOSD patients, with an inverse
correlation between plasma sRAGE levels and disease
activity. Therefore, plasma sRAGE level may serve as abiomarker and negative regulator of inflammation [42],
and the administration of recombinant sRAGE has been
of therapeutic use in inflammatory murine models
[43,44].
As with other previous findings [5,6,21] and similar to
AOSD patients, our SLE patients also had increased
AGEs levels which were positively correlated with SLE-
DAI. On the other hand, active SLE patients had de-
creased plasma sRAGE levels negatively correlated with
disease activity, substantiating the findings that treat-
ment with sRAGE significantly improved nephritis and
histologic renal damage in lupus-prone (NZB/NZW)
mice [45].
There are two possible mechanisms that may explain
the low sRAGE levels in our active AOSD patients. One
is that plasma sRAGE levels may be modulated by its
binding with inflammatory ligands, thereby promoting
consumption of sRAGE [46]. Compatible with this hy-
pothesis, an elevated AGEs levels may increase the bind-
ing and consumption of sRAGE in this study. The other
is that the reduced production of endogenous secretory
sRAGE may not be sufficient as a decoy receptor for
binding inflammatory ligands and therefore there is
weakened protection against the inflammatory response.
The inadequate levels of sRAGE might amplify inflam-
matory responses by increasing the engagement of accu-
mulated AGEs on cell-bound RAGE [19].
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that plasma AGEs levels were positively associated with
the presence of leukocytosis, whereas sRAGE levels
showed negative association. Because cell-bound RAGE
may function as a counter-receptor for leukocyte integrin
Mac-1 and was directly involved in leukocyte recruitment,
sRAGE could act as a potential inhibitor of leukocyte re-
cruitment [47]. In addition, we found that the presence of
anemia in AOSD patients was positively associated with
AGEs levels, but negatively associated with sRAGE levels,
which resonates with the findings that plasma AGEs, a
marker of oxidative stress, was a predictor of anemia in
older community-dwelling adults [48].
The disease courses of AOSD patients may vary con-
siderably. Those with polycyclic disease pattern exhibit
relapsing episodes with systemic inflammation superim-
posed on chronic low-grade inflammation. It is interest-
ing to note that significantly higher AGEs levels were
observed in AOSD patients with polycyclic pattern or
chronic arthritis compared with those with monocyclic
pattern. Cumulative inflammation may contribute to the
increased AGEs levels in AOSD patients with polycyclic
pattern or chronic arthritis, as with the enhanced AGEs
levels positively related to the disease duration of SLE
[5], and the elevation of AGEs levels in RA patients [3].
In contrast, plasma sRAGE levels were lower in AOSD
patients with polycyclic pattern than in those with
monocyclic pattern. Thus, we hypothesize that the dys-
regulated inflammation in patients with polycyclic pat-
tern may persist via insufficient inhibition by sRAGE.
Longitudinal follow-up of our AOSD patients showed
that AGEs levels declined while sRAGE levels increased
with therapy, paralleling the reduction of disease activity.
The change in sRAGE levels after 6-month therapy was
similar to a recent finding that sRAGE levels increased
after long-term (more than one month) treatment [21],
and further supports the potential for AGEs or sRAGE
as a biomarker of disease activity [42].
There were some limitations in our study. Because
AGEs represent a heterogeneous group of compounds,
future studies are needed to determine the major com-
pound which is related to AOSD. The sRAGE may act
as a decoy receptor; however, we still did not elucidate
the functional role of sRAGE in AOSD. Our preliminary
results await further substantiation by ex vivo studies
which will determine interleukin-1 secretion by subjects’
monocytes treated with AGEs or sRAGE.
Conclusions
In conclusion, increased AGEs as well as decreased
sRAGE, which were significantly correlated with disease
activity parameters, may be involved in AOSD pathogen-
esis. We provide the first evidence showing that plasma
levels of AGEs and sRAGE may be linked with diseaseoutcome in AOSD. The results could be of translational
interest, and may potentially lead to the discovery of
novel activity biomarkers [42] or promising therapeutic
targets such as sRAGE, which has been used to protect
against colonic inflammation or autoimmune encephal-
itis [43,44].
Key messages
1. Elevated AGEs levels and decreased sRAGE levels
were observed in both AOSD and SLE.
2. Associations of AGEs and sRAGE levels with disease
activity indicate their involvement in pathogenesis.
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